[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2019006886A - Métodos para tratar enfermedades asociadas con células linfoides innatas del grupo 2 (ilc2). - Google Patents

Métodos para tratar enfermedades asociadas con células linfoides innatas del grupo 2 (ilc2).

Info

Publication number
MX2019006886A
MX2019006886A MX2019006886A MX2019006886A MX2019006886A MX 2019006886 A MX2019006886 A MX 2019006886A MX 2019006886 A MX2019006886 A MX 2019006886A MX 2019006886 A MX2019006886 A MX 2019006886A MX 2019006886 A MX2019006886 A MX 2019006886A
Authority
MX
Mexico
Prior art keywords
methods
diseases associated
treating diseases
ilc2 cells
cells
Prior art date
Application number
MX2019006886A
Other languages
English (en)
Inventor
Henrique Veiga Fernandes José
Rita De Faria Cardoso Vania
Michelle Evelyne Chesne Julie
Original Assignee
Limm Therapeutics Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Limm Therapeutics Sa filed Critical Limm Therapeutics Sa
Publication of MX2019006886A publication Critical patent/MX2019006886A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4642—Invertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/286—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/80—Neurotransmitters; Neurohormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Physics & Mathematics (AREA)

Abstract

En la presente se proporcionan composiciones que incluyen compuestos y/o células para tratar una enfermedad asociada con las celulas linfoides innatas del Grupo 2 (ILC2s), y métodos de tratamiento.
MX2019006886A 2016-12-13 2017-03-29 Métodos para tratar enfermedades asociadas con células linfoides innatas del grupo 2 (ilc2). MX2019006886A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PT18930416 2016-12-13
PCT/IB2017/000413 WO2018109540A1 (en) 2016-12-13 2017-03-29 Methods of treating diseases associated with ilc2 cells

Publications (1)

Publication Number Publication Date
MX2019006886A true MX2019006886A (es) 2019-10-30

Family

ID=58664739

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019006886A MX2019006886A (es) 2016-12-13 2017-03-29 Métodos para tratar enfermedades asociadas con células linfoides innatas del grupo 2 (ilc2).

Country Status (11)

Country Link
US (1) US20190358264A1 (es)
EP (1) EP3554516A1 (es)
JP (2) JP7324707B2 (es)
KR (1) KR20190096379A (es)
CN (1) CN110573168A (es)
AU (1) AU2017378378A1 (es)
BR (1) BR112019011832A2 (es)
CA (1) CA3046884A1 (es)
IL (1) IL267231A (es)
MX (1) MX2019006886A (es)
WO (1) WO2018109540A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115554290A (zh) * 2021-07-01 2023-01-03 中国科学院分子细胞科学卓越创新中心 五羟色胺或其受体激动剂在治疗ilc2细胞介导的免疫性疾病中的应用
CN118580332A (zh) * 2024-08-07 2024-09-03 上海交通大学医学院附属仁济医院 Nmur1特异性抑制多肽及应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5211657A (en) 1988-11-07 1993-05-18 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides
EP1471927A2 (en) * 2002-02-06 2004-11-03 Bayer Aktiengesellschaft Diagnostics and therapeutics for diseases associated with neuromedin u1 receptor (nmu1)
US20090089889A9 (en) * 2006-01-18 2009-04-02 Chen Howard Y Neuromedin u receptor subtype 1 deficient transgenic mice and uses thereof
KR20090005329A (ko) 2006-03-20 2009-01-13 머크 앤드 캄파니 인코포레이티드 뉴로메딘 ｕ 수용체 효능제 및 이의 용도
US20110165144A1 (en) 2006-08-16 2011-07-07 Joslin Diabetes Center, Inc. Methods for treating rheumatoid arthritis
US20110301079A1 (en) * 2007-09-21 2011-12-08 Instituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Neuromedin u receptor agonists and uses thereof
US20100286035A1 (en) 2007-10-05 2010-11-11 Takeda Pharmaceutical Company Limited Neuromedin u derivative
WO2010053830A1 (en) * 2008-11-05 2010-05-14 Merck Sharp & Dohme Corp. Mechanism of neuromedin u action and uses thereof
WO2010116752A1 (ja) * 2009-04-08 2010-10-14 武田薬品工業株式会社 ニューロメジンｕ誘導体
WO2010138343A1 (en) 2009-05-27 2010-12-02 Merck Sharp & Dohme Corp. Neuromedin u receptor agonists
WO2011005611A1 (en) 2009-07-09 2011-01-13 Merck Sharp & Dohme Corp. Neuromedin u receptor agonists and uses thereof
JP2013209295A (ja) 2010-10-13 2013-10-10 Takeda Chem Ind Ltd ペプチド誘導体
WO2016090250A1 (en) * 2014-12-04 2016-06-09 The University Of North Carolina At Chapel Hill Compositions and methods for preventing and treating graft versus host disease
US10294297B2 (en) * 2016-01-29 2019-05-21 The Board Of Trustees Of The Leland Stanford Junior University Methods for treatment using anti-NMU agents

Also Published As

Publication number Publication date
BR112019011832A2 (pt) 2019-10-22
KR20190096379A (ko) 2019-08-19
WO2018109540A1 (en) 2018-06-21
US20190358264A1 (en) 2019-11-28
JP2022050478A (ja) 2022-03-30
CA3046884A1 (en) 2018-06-21
EP3554516A1 (en) 2019-10-23
CN110573168A (zh) 2019-12-13
JP2020511418A (ja) 2020-04-16
JP7324707B2 (ja) 2023-08-10
AU2017378378A1 (en) 2019-07-04
IL267231A (en) 2019-08-29

Similar Documents

Publication Publication Date Title
MX2018011114A (es) Métodos y composiciones relacionadas con crispr/cas para el tratamiento de beta hemoglobinopatías.
MY192888A (en) Dna alkylating agents
MX2017005252A (es) Metodos para la preparacion de ribosidos.
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
GB2541571A (en) Pharmaceutical compositions
MY198613A (en) Nitrobenzyl derivatives of anti-cancer agents
MD4733C1 (ro) Anticorpi anti-TIGIT
MX2020001757A (es) Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
SA518391864B1 (ar) مشتقات باي بيرازوليل مفيدة لمعالجة أمراض المناعة الذاتية
PH12018502056A1 (en) Methods of treatment of cholestatic diseases
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
ZA201807438B (en) Methods of treating ocular conditions
MX2022006817A (es) Formulaciones/composiciones que comprenden un inhibidor de btk.
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
MX2017005522A (es) Tratamiento novedoso de la cornea usando laminina.
PH12017500602A1 (en) Methods for treating ocular conditions
MX2018009662A (es) Metodo y composicion farmaceutica para tratamiento de neurodegeneracion.
MX2019004804A (es) Tratamiento para el prurigo nodula.
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.
MX2019006886A (es) Métodos para tratar enfermedades asociadas con células linfoides innatas del grupo 2 (ilc2).
WO2018211324A8 (en) Prodrugs for the treatment of disease
PH12017500998A1 (en) Treatment of ocular conditions using progenitor cells
MX2018013885A (es) Métodos de tratamiento de enfermedades asociadas con células linfoides innatas del grupo 3 (cli3).